{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T05:04:10Z","timestamp":1731128650773,"version":"3.28.0"},"reference-count":40,"publisher":"Baishideng Publishing Group Inc.","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["World J Gastrointest Oncol"],"abstract":"<jats:p>BACKGROUND<\/jats:p>\n          <jats:p>Transhepatic arterial chemoembolization (TACE), as a local treatment, has been widely used in the treatment of unresectable liver cancer. The introduction of drug carrier microspheres has brought new hope for the therapeutic effect of TACE. Microspheres can realize the slow release and directional delivery of drugs, reduce systemic toxicity and improve local curative effect.<\/jats:p>\n          <jats:p>AIM<\/jats:p>\n          <jats:p>To compare the effectiveness of traditional transcatheter arterial chemoembolization against microsphere-assisted transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma that is incurable.<\/jats:p>\n          <jats:p>METHODS<\/jats:p>\n          <jats:p>We searched the PubMed, Embase, Cochrane Library, and CNKI databases for clinical trials of drug-luting beads TACE (DEB-TACE) vs  conventional TACE (cTACE) for the treatment of unresectable liver cancer. We screened references based on inclusion and exclusion criteria and then selected valid data for meta-analysis using RevMan 53 software. The complete response (CR) rate, partial response (PR) rate, postoperative stable disease (SD) rate, and 6-month and 12-month survival rates were compared.<\/jats:p>\n          <jats:p>RESULTS<\/jats:p>\n          <jats:p>A total of 12 articles were included, including 1177 patients, 519 of whom received DEB-TACE and 658 of whom received cTACE. The CR rate in the DEB-TACE group was much greater than that in the cTACE group [relative risk (RR) = 1.42, 95%CI: 1.18\u20131.72, P  = 0.0002]. The 12-month survival rate significantly increased (RR = 1.09; 95%CI: 1.01- 1.17, P  = 0.03); the PR rate (RR = 1.13; 95%CI: 0.97-1.30, P  = 0.12); the SD rate (RR = 0.82; 95%CI: 0.64-1.05, P  = 0.12); and the 6-month survival rate (RR = 1.05; 95%CI: 1.00-1.10, P  = 0.07). There was no significant difference (P  &lt; 0.05).<\/jats:p>\n          <jats:p>CONCLUSION<\/jats:p>\n          <jats:p>Compared with those of iodized oil TACE, the drug-loaded microspheres tended to have therapeutic advantages.<\/jats:p>","DOI":"10.4251\/wjgo.v16.i12.4728","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:17:27Z","timestamp":1731046647000},"page":"4728-4737","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of transhepatic arterial chemoembolization with drug-loaded microspheres in unresectable primary liver cancer"],"prefix":"10.4251","volume":"16","author":[{"given":"Jun","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Hong","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Le","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong-Xing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Jun","family":"Long","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Yong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-Cai","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2060","published-online":{"date-parts":[[2024,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1080\/09205063.2014.982242"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18632\/aging.202860"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.131494"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2020.00188"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-023-07984-4"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10092248"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02529-x"},{"key":"B8","unstructured":"Liu S, Yu G, Wang Q, Li L, Liu Y, Du K, Zhang F, Zhao B, Zhao G. CalliSpheres(\u00ae) microspheres drug-eluting bead transhepatic artery chemoembolization with or without sorafenib for the treatment of large liver cancer: a multi-center retrospective study. Am J Transl Res 2021; 13: 13931-13940"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fsurg.2022.981116"},{"key":"B10","unstructured":"Chen G, Zhang D, Ying YC, Wang ZF, Tao W, Zhu H, Zhang JF, Peng ZY. [Clinical study on the treatment of unresectable primary liver cancer by transarterial chemoembolization with Chinese drug-carrying microspheres]. hejiang Daxue Xuebao; Yixue Kexueban 2017; 46: 44-51"},{"key":"B11","unstructured":"Chi Q, Zhang L, Liu B, Zhang GA. [Efficacy of Epirubicin combined with iodide and Hepas phere drug-loaded microspheres in the treatment of TACE in patients with liver cancer]. Xiandai Zhongliu Yixue 2018; 26: 2090-2093"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rx.2010.07.010"},{"key":"B13","unstructured":"Huang YJ, Ling YZ, Qin ZL. [Efficacy of HepaSphere drug-loaded microspheres in the treatment of primary liver cancer]. Linchuang Yixue Zazhi 2018; 38: 35-36"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-009-9711-7"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.4523"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-009-9750-0"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2011.07.002"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2012.07.017"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881714"},{"key":"B20","unstructured":"You JX, Wang JB, Ai ST, Fan XD, Zheng LZ, Su LX, Wen MZ, Yang XT. [Effect of microspheres combined with liodoembolization in the treatment of hepatocellular carcinoma]. Jieru Fangshexue Zazhi 2017; 26: 531-534"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21522"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11071861"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000000256"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5125"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/kjm2.12613"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001189"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-02906-1"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000001319"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/5492931"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.36922\/ijb.1256"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45348"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.117072"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2023.2203387"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v44i3.36961"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020186"},{"key":"B36","unstructured":"Wang J, Huang A, Fu P, Chen X, Zhang X, Yin Y, Zhou J. Effects of TACE combined with microwave ablation on T lymphocyte subsets and prognosis in patients with liver cancer and analysis of safety. J BUON 2020; 25: 1883-1889"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013345.pub2"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e28282"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/00015458.2023.2256539"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-023-00574-7"}],"container-title":["World Journal of Gastrointestinal Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i12\/4728.htm","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i12\/4728.htm","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T06:18:24Z","timestamp":1731046704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.wjgnet.com\/1948-5204\/full\/v16\/i12\/4728.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,15]]},"references-count":40,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.4251\/wjgo.v16.i12.4728","relation":{},"ISSN":["1948-5204"],"issn-type":[{"value":"1948-5204","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,15]]}}}